ESR1 and breast carcinoma: Tamoxifen is a compound that has been developed as an ER antagonist for ERα positive breast cancer treatment [1–4] whereas tamoxifen acts as an agonist of ER in bone metabolism, resulting in the up-regulation of bone mass [1–4].